Healthcare

Rheumatoid Arthritis Drugs Market Worth US$ 70 Bn by 2030

The global rheumatoid arthritis drugs market is on the rise. According to research and consulting company, Precedence Research, the market size of rheumatoid arthritis drugs worldwide will hit US$ 70 billion by 2030, up from US$ 61.05 billion in 2022. This means a cumulative average growth rate (CAGR) of 1.72% from 2022 to 2030. The report contains 150+ pages with detailed analysis.

Rheumatoid Arthritis Drugs Market Size 2021 to 2030

The increased prevalence of rheumatoid arthritis is one of the major reasons driving the global rheumatoid arthritis medications market. According to a study published in November 2020, the global prevalence of rheumatoid arthritis was anticipated to be 0.46% based on a systematic review. As a result, more rheumatoid arthritis treatments will be prescribed, propelling the market for these medications forward. Increased launches of novel biologics and rising generic medicine penetration are projected to boost the global rheumatoid arthritis pharmaceuticals market significantly.

Growing patient knowledge of rheumatoid arthritis problems is another factor driving the global rheumatoid arthritis medications market. The worldwide rheumatoid arthritis medications industry is also being propelled forward by government authorities’ increasing efforts.

Rheumatoid Arthritis Drugs Market Report Scope

Report CoverageDetails
Market Size by 2030USD 70 Billion
Growth Rate from 2022 to 2030CAGR of 1.72%
Largest MarketNorth America
Fastest Growing MarketAsia-Pacific
Base Year2021
Forecast Period2022 to 2030
Segments CoveredMolecule, Sales Channel, Route of Administration, Geography

Download a FREE Sample Copy (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1755

Rheumatoid Arthritis Drugs Market Report Highlights

  • On the basis of molecule type, biologics segment holds the largest market share in the global rheumatoid arthritis drugs market. Biological pharmaceuticals are expected to account for the majority of revenue in established nations over the predicted period. Due to the high cost of biologics, these treatments face significant competition from biosimilars and generic pharmaceuticals in emerging nations.
  • On the basis of sales channel, prescription drugs segment holds the largest market share in the global rheumatoid arthritis drugs market. Overuse of rheumatoid arthritis drugs for a long time can develop to treatment resistance, thus patients with this disorder should see a rheumatologist and follow their recommendations.

Rheumatoid Arthritis Drugs Market Regional Snapshot

North America region is the fastest growing region in the rheumatoid arthritis drugs market. The U.S. hold the highest market share in the North America rheumatoid arthritis drugs market. According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million people. In addition, the Canadian government estimates that 374,000 Canadians aged 16 and up suffer from rheumatoid arthritis. Because of the disease’s extensive prevalence, more medicines will be taken, leading in a growth in the rheumatoid arthritis drugs market in North America.

Asia-Pacific is the largest segment for rheumatoid arthritis drugs market in terms of region.China and Indiaare dominating the rheumatoid arthritis drugs market in the Asia-Pacific region. Rising knowledge of disease remission therapy, high public and private healthcare expenditure, and rising rheumatoid arthritis incidences are all driving the Asia-Pacific rheumatoid arthritis medications market. Furthermore, easy access to high-quality healthcare, a solid clinical product range, favorable reimbursement standards, and the approval of novel medications are projected to boost revenue growth in the Asia-Pacific area.

Rheumatoid Arthritis Drugs Market Dynamics

Drivers: Surge in prevalence of rheumatoid arthritis

The ageing population is mainly accountable for the rising incidences of rheumatoid arthritis. Furthermore, some evidence suggests that smokers are more likely to develop rheumatoid arthritis. The rise in the senior population, higher usage of traditional disease modifying antirheumatic drugs, and government measures to disseminate awareness of rheumatoid arthritis symptoms are the primary drivers driving the growth of global rheumatoid arthritis drugs market.

Restraints: Lack of awareness and high cost of rheumatoid arthritis drugs

The key limits of the global rheumatoid arthritis drugs market are expected to be medication related undesirable effects and high pricing of biological disease modifying antirheumatic drugs therapy. The most significant market limitation is the high cost of pharmaceuticals, as therapy is far more expensive and the average person cannot afford it in cases where there is no cure for the disease. The global rheumatoid arthritis drugs market is projected to face challenges due to a lack of awareness, particularly in emerging nations.

Also Read:- Artificial Intelligence in Life Sciences Market Value – US$ 6.7 Bn By 2030

Opportunities: Growing advancements in biologics

Theadvances in sophisticated biologics, increased purchasing power, increased healthcare expenditure, and worldwide access to high quality medications for middle and poor class families are all contributing factors. On the other hand, due to enhanced treatment regarding early treatment and screening of rheumatoid arthritis, the global rheumatoid arthritis drugs market is predicted to rise quickly and shift the market outlook. As a result, growing advancements in biologics is creating lucrative opportunities for the growth of global rheumatoid arthritis drugs market.

Challenges: Lack of resources in underdeveloped nations

The underdeveloped countries do not have enough resources for the development of rheumatoid arthritis drugs. As a result, lack of resources in underdeveloped nations is a major challenge for the expansion of worldwide rheumatoid arthritis drugs market.

Rheumatoid Arthritis Drugs Market Recent Developments

  • Xbrane Biopharma AB and Biogen Inc. signed a commercialization and license agreement in February 2022 to develop, produce, and market Xcimzane, a preclinical monoclonal antibody that is suggested biosimilar of CIMZIA for the treatment of rheumatoid arthritis.
  • The Food & Drug Administration approved Pfizer’s biosimilar, abriladaTM, for a number of inflammatory disorders, particularly rheumatoid arthritis, in November 2019.
  • ROS Therapeutics, is developing a targeted methotrexate prodrug to reduce toxicity in the treatment of patients with rheumatoid arthritis.
  • In 2020, Bayer AG announced that it would invest around $59 million in the establishment of new manufacturing and supply facility at Beijing Economic Technological Development.

Rheumatoid Arthritis Drugs Market Key Players:

  • AbbVie
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • UCB S.A.
  • Johnson & Johnson Services, Inc.
  • Amgen, Inc.

Segments Covered in the Report

By Molecule

  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
      • TNF-α antagonists
      • T-cell inhibitors
      • CD20 antigen
      • JAK inhibitors
      • anti-IL6 biologics
    • Biosimilars
      • CD20 antigen
      • TNF-α antagonists

By Sales Channel

 By Route of Administration

  • Oral
  • Parenteral

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Research Methodology

A unique research methodology has been utilized to conduct comprehensive research on the growth of the global rheumatoid arthritis drugs market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions.

Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.

These primary and secondary sources provided exclusive information during interviews, which serves as validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global rheumatoid arthritis drugs market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimate the future prospects of the global market more reliable and accurately.

Why should you invest in this report?

If you are aiming to enter the global rheumatoid arthritis drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for rheumatoid arthritis drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Rheumatoid Arthritis Drugs Market 

5.1. COVID-19 Landscape: Rheumatoid Arthritis Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Rheumatoid Arthritis Drugs Market, By Molecule

8.1. Rheumatoid Arthritis Drugs Market, by Molecule, 2022-2030

8.1.1 Pharmaceuticals

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Biopharmaceuticals

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel

9.1. Rheumatoid Arthritis Drugs Market, by Sales Channel, 2022-2030

9.1.1. Prescription

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Over-the-Counter (OTC)

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Rheumatoid Arthritis Drugs Market, By Route of Administration 

10.1. Rheumatoid Arthritis Drugs Market, by Route of Administration, 2022-2030

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Parenteral

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Rheumatoid Arthritis Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.1.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Molecule (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Sales Channel (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)

Chapter 12. Company Profiles

12.1. AbbVie

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Boehringer Ingelheim GmbH

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Novartis AG

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Regeneron Pharmaceuticals, Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pfizer, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bristol-Myers Squibb Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. F. Hoffmann-La Roche Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. UCB S.A.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Johnson & Johnson Services, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Amgen, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1755

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Show More

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Back to top button